Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

12.62 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Deciphera Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing. 
Via InvestorPlace
3 Under-the-Radar Biotech Stocks to Buy in 2023
All three biotech companies focus on oncology therapies. 
Via The Motley Fool
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Earnings Preview: Deciphera Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
Via Benzinga
Recap: Deciphera Pharmaceuticals Q1 Earnings
Via Benzinga
Preview: Deciphera Pharmaceuticals's Earnings
Via Benzinga
Why Shares of Deciphera Pharmaceuticals Rose This Week
The company's shares rose after the company reported second-quarter earnings. 
Via The Motley Fool
Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst
Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
Where Deciphera Pharmaceuticals Stands With Analysts
Via Benzinga
Looking Into Deciphera Pharmaceuticals's Return On Capital Employed
Via Benzinga
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on... 
Via Benzinga
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Why Deciphera Pharmaceuticals Stock Jumped This Week
The company's lead therapy received an FDA Breakthrough Therapy designation. 
Via The Motley Fool
Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space
Via Benzinga
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.